Abstract OT1-08-05: Phase II trial of GDC-0084 in combination with trastuzumab for patients with HER2-positive breast cancer brain metastases (BCBM)

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-4852-5 ◽

2018 ◽

Vol 171 (3) ◽

pp. 637-648 ◽

Cited By ~ 14

Author(s):

Amanda E. D. Van Swearingen ◽

Marni B. Siegel ◽

Allison M. Deal ◽

Maria J. Sambade ◽

Alan Hoyle ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Her2 Positive ◽

Abstract P5-19-07: Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3

10.1158/1538-7445.sabcs14-p5-19-07 ◽

2015 ◽

Cited By ~ 2

Author(s):

Javier Cortés ◽

Veronique Dieras ◽

Jungsil Ro ◽

Jérôme Barriere ◽

Thomas Bachelot ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Trial ◽

Her2 Positive ◽

Randomized Phase Ii ◽

Choice Of Treatment ◽

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases

Journal of Neuro-Oncology ◽

10.1007/s11060-011-0629-y ◽

2011 ◽

Vol 105 (3) ◽

pp. 613-620 ◽

Cited By ~ 111

Author(s):

Nancy U. Lin ◽

Wolfgang Eierman ◽

Richard Greil ◽

Mario Campone ◽

Bella Kaufman ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Her2 Positive ◽

Randomized Phase Ii ◽

Abstract OT1-1-15: LUX-Breast 3: Randomized Phase II trial of afatinib (BIBW 2992) alone or with vinorelbine versus investigator's choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases after trastuzumab and/or lapatinib-based therapy*

10.1158/0008-5472.sabcs12-ot1-1-15 ◽

2012 ◽

Cited By ~ 1

Author(s):

H Joensuu ◽

M Ould-Kaci

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Trial ◽

Her2 Positive ◽

Bibw 2992 ◽

Randomized Phase Ii ◽

Choice Of Treatment ◽

Faculty Opinions recommendation of Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.724195112.793501041 ◽

2014 ◽

Author(s):

Minesh Mehta ◽

Manmeet Ahluwalia

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Her2 Positive ◽

Multicenter Phase ◽

Abstract PS13-14: A randomized, opened, phase II trial assessing the efficacy and safety of ATH-TH(doxorubicin/docetaxel/trastuzumab followed by docetaxel/trastuzumab) versus TCH(docetaxel/carboplatin/trastuzumab) as neoadjuvant treatment in HER2-positive breast cancer

10.1158/1538-7445.sabcs20-ps13-14 ◽

2021 ◽

Author(s):

Tao Wang ◽

Jin-Mei Zhou ◽

Xiao-Peng Hao ◽

Hui-Qaing Zhang ◽

Shao-Hua Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Neoadjuvant Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer – A phase II study

Journal of the Egyptian National Cancer Institute ◽

10.1016/j.jnci.2014.08.001 ◽

2014 ◽

Vol 26 (4) ◽

pp. 187-194 ◽

Cited By ~ 9

Author(s):

Hanan Shawky ◽

Hesham Tawfik

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Her2 Positive ◽

Abstract P1-08-36: Neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER). Analysis of biomarkers

10.1158/0008-5472.sabcs13-p1-08-36 ◽

2013 ◽

Author(s):

M Fernández ◽

N Martinez ◽

I Calvo ◽

E Garcia ◽

L Ugidos ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Neoadjuvant Treatment ◽

Weekly Paclitaxel ◽

Her2 Positive ◽

Abstract 4832: Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases

10.1158/1538-7445.am2019-4832 ◽

2019 ◽

Cited By ~ 1

Author(s):

Jing Ni ◽

Yanzhi Wang ◽

Irmina Diala ◽

Sheheryar Kabraji ◽

Rachel Freedman ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Her2 Positive ◽

Preclinical Evaluation ◽

Pdx Models ◽

Abstract A48: Ado-trastuzumab emtansine (T-DM1) controls tumor progression of established HER2-positive breast cancer brain metastases in mice

10.1158/1538-7445.tummet15-a48 ◽

2016 ◽

Author(s):

Gino B. Ferraro ◽

Vasileios Askoxylakis ◽

David P. Kodack ◽

Mark Badeaux ◽

Dai Fukumura ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Tumor Progression ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽